open access
IUMPA–2: release of medroxyprogesterone acetate from the intrauterine system in the treatment of endometrial hyperplasia relative to the patient's body mass index (BMI)
open access
Abstract
Aim
First, to develop a system of an intrauterine diaphragm with medroxyprogesterone acetate in the treatment of endometrial hyperplasia. Second, to check the distribution of this drug depending on the patient's BMI.
Materials and methods
The study comprised a group of 20 postmenopausal patients with histologically diagnosed simple hyperplasia treated with IUMPA-2 using endoscopic techniques (hysteroscopic targeted endometrial biopsy), histological methods (bioptate assessment) and ultrasound techniques (treatment volume and endometrial measurements).
Results
In all patients investigated the rate of medroxyprogesterone acetate release increased with BMI, which had an effect on the treatment time ranging between 35 and 14 days, respectively.
Conclusions
1) The BMI affects the rate of medroxyprogesterone acetate release from IUMPA-2. 2) In patients with a high BMI double (sequentially) application of a diaphragm should be considered.
Abstract
Aim
First, to develop a system of an intrauterine diaphragm with medroxyprogesterone acetate in the treatment of endometrial hyperplasia. Second, to check the distribution of this drug depending on the patient's BMI.
Materials and methods
The study comprised a group of 20 postmenopausal patients with histologically diagnosed simple hyperplasia treated with IUMPA-2 using endoscopic techniques (hysteroscopic targeted endometrial biopsy), histological methods (bioptate assessment) and ultrasound techniques (treatment volume and endometrial measurements).
Results
In all patients investigated the rate of medroxyprogesterone acetate release increased with BMI, which had an effect on the treatment time ranging between 35 and 14 days, respectively.
Conclusions
1) The BMI affects the rate of medroxyprogesterone acetate release from IUMPA-2. 2) In patients with a high BMI double (sequentially) application of a diaphragm should be considered.
Keywords
IUMPA; hormone treatment; endometrial hyperplasia
About this articleTitle
IUMPA–2: release of medroxyprogesterone acetate from the intrauterine system in the treatment of endometrial hyperplasia relative to the patient's body mass index (BMI)
Journal
Reports of Practical Oncology and Radiotherapy
Issue
Pages
73-75
Published online
2004-01-01
DOI
10.1016/S1507-1367(04)71012-3
Bibliographic record
Rep Pract Oncol Radiother 2004;9(3):73-75.
Keywords
IUMPA
hormone treatment
endometrial hyperplasia
Authors
Andrzej J. Kowalski
Jakub Welfel
Jacek Suzin